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Abstract A study of the assessment criteria covers the synthesis and characterization of agent and test their biological 
effectiveness as boron neutron capture therapy (BNCT) agents in cancer treatment. The cellular uptake of this agent into 
the glioblastoma cells was assessed by boron analysis (ICP-MS) and by fluorescence imaging (confocal microscopy). 
The agent enters the glioblastoma cells exhibiting a similar profile, i.e., preferential accumulation in the cytoskeleton 
and membranes and a low cytotoxic activity (IC50 values higher than 200 μM). The cyto toxic activity and cellular 
morphological alterations after neutron irradiation in the Research Reactor (>107 neutrons cm−2 s−1) were assessed by 
the MTT assay and by electron microscopy (TEM). Post neutron irradiation revealed that BNCT has a higher cytotoxic 
effect on the glioblastoma cells. Results provide a strong rationale for considering one of these compounds as a lead 
candidate for a new BNCT agent. 
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INTRODUCTION 
Malignant gliomas are the most common 
type of primary malignant brain tumor and 
the most frequently found brain tumor 
diagnosed in up to 49% of cases. According 
to the World Health Organization (WHO) 
glioblastoma or grade IV glioma is the most 
common form of gliomas and represents one 
of the most aggressive and treatment resistant 
types of  human cancer were reviewed by A. 
Omuro et al and M. M. Mrugala. 
Glioblastoma remains an incurable disease 
despite technological and therapeutic 
improvements in surgery, radiotherapy and 
chemotherapy or combined therapeutic 
modalities. The outlook has improved only 
modestly,  and the survival rate of patients 
stays less than a few percent were reviewed 
by C. Caruso et al, and C. P. Tanase et al.  
The therapeutic challenge is to develop 
strategies that can selectively target malignant 
cells, with little or no effect on normal cells and 
tissues adjacent to the tumor. One such approach 
is the so-called “binary therapy” in which two 
non-toxic components can be combined in order 
to produce a cytotoxic effect. The advantage is 
that each component can be modulated and 
manipulated independently to maximize the 
therapeutic efficacy.  A potentially useful binary 
system is the boron neutron capture therapy 
(BNCT). As a binary treatment modality, BNCT 
combines a radiosensitizer, 10B (19.8 % natural 
abundance) with thermal neutrons (n), an 
indirectly ionizing radiation.  The subsequent 
(n,α) reaction yields 1.47 MeV α particles and 
0.84 MeV 7Li ions, both having high linear 
energy transfer (LET) causing radiotoxic effects 
in the range of a cell diameter (ca. 10 μm). The 
efficient energy transfer produces selective 
damage in the cells containing 10B so that boron 
content and distribution in tumor are pivotal to 
the therapeutic efficacy of this treatment 
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modality were reviewed by R. F. Barth et al , 
R. F. Barth and T. Yamamoto et al.  
Boron atoms have to be targeted to 
tumor cells using a suitable boron carrier in 
order to maximize tumor cell damage and 
minimize the total radiation dose to the 
patient.  The boron drugs sodium borocaptate 
(BSH) and boronophenylalanine (BPA) have 
been extensively assessment and are currently 
approved to treat glioma, melanoma, head 
and neck tumors and hepatocarcinoma were 
reviewed by M. A. Pisarev et al, S. Altieri et 
al and T. Kageji et al.  These compounds are 
however far  from ideal, exhibiting 
insufficient selectivity and efficiency, besides 
other limitations such as a reduced capability 
to cross the blood–brain barrier (BBB) and a 
poor water solubility  (BPA) were reviewed 
by R. F. Barth et al, D. R. Lu, S. C. Mehta et 
al and A. H. Soloway et al.  The subcellular 
distribution of these compounds in a glioma 
cell model showed that most of the boron was 
localized in the cytoplasm of the cells, but 
only minimal concentrations of boron existed 
in the nuclei were reviewed by T. Nguyen et 
al.   A major challenge in the development of 
boron delivery agents is to deliver a sufficient 
amount of boron into the tumor cells to 
maximize the doses of radiation to the tumor 
with minimal normal tissue toxicity were 
reviewed by R. Gahbauer et al.     
The use of boron clusters such as a 
dodecarborane instead of single boron atoms 
allows increasing the loading ability. 
Moreover, dodecarborane contains 10 boron 
atoms and possesses a rather low cytotoxicity 
and is compatible and extremely stable in 
biological medium were reviewed by I. B. 
Sivaev et al and  C. Viñas i Teixidor et al. To 
increase the selectivity and efficacy of 
dodecarboranes towards cancer cells a large 
variety of derivatives have been designed and 
evaluated, taking into account specific features 
of cancer cells, such as enhanced metabolism 
and over-expression of target receptors were 
reviewed by C. H. Hsieh et al, A. Crivello et al, 
T. Betzel et al, J. Bonjoch et al and W. Yang et 
al. DNA binding agents and tumor seeking 
molecules like porphyrins and porphyrinic 
macrocyclic compounds, such as  
phthalocyanines, are also alternatives for 
selective delivery of the boron moiety into tumor 
cells were reviewed by R. P. Evstigneeva et al, 
M. W. Easson et al, E. L. Crossley et al, J. Yoo 
et al and N. P. Barry et al.   However, until now 
there has been no new boron compound that has 
reached the stage for phase I clinical trials. Both 
BSH and BPA still remain today as the only two 
drugs in clinical trials for BNCT were reviewed 
by R. L. Moss et al. 
Research on BNCT involves the design, 
synthesis and evaluation of more selective tumor 
targeting agents. The close proximity of the 
boron agent to DNA of tumor cells is also highly 
desirable. In addition, these compounds have 
attracted considerable attention from the 
scientific community due to their wide range of 
biological activities were reviewed by P. 
Belmont et al, G. Cholewiński et al and M. 
Koba et al. These results may offer new insights 
for consideration in malignant glioma treatment 
strategies. 
MATERIAL AND EQUIPMENT 
Most of the reagents used highly dependent 
on the compounds synthesized.  All reagents 
were used without further purification.  The 
internal standard was TMS. Nitrogen was used 
as a nebuliser gas and argon as a collision gas.  
Equipments used NMR and Thin Layer 
Chromatography. NMR spectra were recorded 
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on Bruker Avance 300 (300.13 MHz for 1H 
and 75.47 MHz for 13C) and Bruker Avance 
500 (500.13 MHz for 1H and 125.76 MHz for 
13C) spectrometers, using CDCl3 as a solvent. 
Preparative thin layer chromatography was 
carried out with Riedel silica gel 60 DGF254 
and column chromatography using Acros 
silica gel 60, 35–70 μm. 
Synthesis 
Most of the reagents used highly dependent 
on the compounds synthesized.  As an example 
of the synthesized compounds can be seen in 
Figure 1. 
 
Characterization 
Characterization a new BNCT agent 
using NMR equipment and Thin Layer 
Chromatography. 
Cell studies 
Cell culture and cellular viability. As an 
example human glioblastoma multiforme cell 
lines were cultured in DMEM with GlutaMax 
I (Gibco) containing 10% fetal bovine serum 
and 1% antibiotics under a humidified 
atmosphere (95% air/5% CO2) at 37°C. The 
cytotoxic activity of the boron compounds was 
determined using the MTT assay {MTT = [3-
(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide]} was described E. 
Vega-Avila et al.   
The cellular viability was evaluated by 
comparing the absorbance of the resulting 
solutions at 570 nm for the treated cells with the 
absorbance for non-treated cells in a multi-well 
plate spectrophotometer. The cytotoxic activity 
of the compounds was quantified by calculating 
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the drug concentration inhibiting tumor cell 
growth by 50% (IC50), based on non-linear 
regression analysis of dose response data 
(GraphPad Prism software). All compounds 
were tested in at least two independent 
experiments, each comprising eight replicates 
per concentration. 
Dosimetry 
The Research Reactor was used as a 
neutron source for in vitro cell irradiation.   
Neutron irradiation was carried out at the 
vertical access of the thermal column of the 
Research Reactor, consisting of a graphite 
stacking that moderates the fission neutrons. 
Cell irradiation is performed on top of the 
graphite using an experimental design similar 
to that described by A. Irles et al and N. G. 
Oliveira et al. The radiation field at the 
irradiation facility was calculated using a 
general-purpose Monte Carlo code for 
radiation transport simulation and a detailed 
model which included a validated model of 
the reactor core was described A. C. 
Fernandes et al. The calculated neutron 
energy distribution was further adjusted via 
the multiple-foil activation method and 
standard unfolding codes. The intensity of the 
neutron beam varies with the distance from 
the core, i.e., is constant (within ± 3%) in the 
parallel direction and decreases with 
increasing distance with a larger relative 
contribution of thermal neutrons as more 
graphite is traversed. The conventional 
thermal neutron fluence rate (ϕ0) at the 
highest intensity position is > 107 neutrons 
cm−2 s−1; the ratio between the epithermal 
neutron fluence rate per unit lethargy (θ) and 
ϕ0 varies between 0.03% and 0.05% in the 
cell flask location. The contribution of 
epithermal neutrons to the dose received by 
the boron loaded cells is therefore negligible. 
Regarding photon doses, low neutron 
sensitivity thermoluminescent dosimeters of 
Al2O3:Mg,Y were used to evaluate the accuracy 
of the photon simulations and measure the 
photon dose itself. It was concluded that the 
major (>99%) contribution to the photon dose is 
neutron interactions with the facility materials; 
therefore, a direct relation between the photon 
dose and the thermal neutron fluence can be 
derived. Details of the procedures was described 
Fernandes et al. The neutron fluence and photon 
dose received by the cells in the actual 
irradiation was monitored using pure gold foils 
underneath the cell flasks. The ratio of the foil 
response to the thermal and epithermal neutron 
fluence rates and to the photon dose rate was 
previously determined in a calibration run. 
In vitro cell neutron irradiation 
Prior to irradiation, the cells in culture 
flasks at a density of approximately 106 cells per 
5 mL medium were pre-incubated for 1 h with 
the compounds at a concentration of 200 μM in 
medium. Thereafter the cells were irradiated at 
room temperature for 5 h.  
The maximum discrepancy between the 
measurements and this reported value is 17% 
due to the neutron fluence gradient within the 
irradiation facility. Exponentially growing cells 
were distributed in the following groups: (1) 
untreated cells without neutrons; (2) cells + 
neutrons; (3) cells with the compounds at 200 
μM without neutrons; and (4) cells with the 
compounds at 200 μM + neutrons. Cells that 
have not been treated with the boron compounds 
were used as controls. Following irradiation, the 
cells were placed in boron free medium under a 
humidified atmosphere containing 5% CO2 at 
37°C. After 24 h the cellular viability was 
evaluated by the MTT assay. The absorbance of 
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the resulting solutions was measured at 570 
nm using a Varian DMS 80 UV-Vis 
spectrophotometer. 
Boron analysis by ICP-MS 
The total cellular boron content was 
analysed by Inductively Coupled Plasma 
Mass Spectrometer (ICP-MS). The 
glioblastoma cells (approx. 106 cells/5 mL 
medium) were exposed to the compounds at 
200 μM for 6 h at 37°C, and then washed 
with ice-cold PBS and centrifuged to obtain a 
cellular pellet. The cytosol, 
membrane/particulate, cytoskeletal and 
nuclear fractions were extracted using a 
FractionPREP™ cell fractionation system 
(BioVision, USA) and performed according 
to the manufacturer’s protocol. The boron 
content in the different fractions was 
measured after digestion of the samples in a 
closed pressurized microwave digestion unit 
(Mars5, CEM) with medium pressure HP500 
vessels and then diluted in ultrapure water to 
obtain 2.0% (v/v) nitric acid. The instrument 
was tuned using a multielement ICP-MS 71 C 
standard solution (Inorganic Venture). Indium 
(115In) at 10 mM was used as the internal 
standard. 
Uptake by fluorescence microscopy 
Cellular uptake of compounds was 
visualized by performing time-lapse confocal 
microscopy imaging of live cells.  
Cells were imaged using a Zeiss LSM 
510 META inverted laser scanning confocal 
microscope (Carl Zeiss, Germany) fitted with 
a large incubator at 37°C (Pecon, Germany) 
using a PlanApochromat 63/1.4 oil-
immersion objective. Ethidium bromide 
fluorescence was detected using the 514 nm 
laser line of an argon laser (45 mW nominal 
output) and a 530–600 nm band-pass filter. 
Hoechst fluorescence was detected using a diode 
405 nm laser (50 mW nominal output) and a 
420–480 nm band-pass filter. The fluorescence 
of 4a was detected using the 420–480 nm band-
pass filter. A transmission detector (PMT) was 
used to provide a transmission light image of the 
sample by detecting the scanning 488 nm laser. 
The pinhole aperture was adjusted in both 
channels to achieve the same optical slice 
thickness (1 μm). 
Ultrastructural analysis 
After irradiation (cells ± compounds + 
neutrons) the culture medium was replaced by a 
primary fixative (5 mL) consisting of 
glutaraldehyde (3%) in sodium cacodylate buffer 
(pH 7.3, 0.1 M). After primary fixation for 2 h at 
4°C, the glutaraldehyde was replaced by sodium 
cacodylate buffer. The cells were scraped, 
pelleted, and embedded in agar (2%) for further 
processing. The samples were washed in 
cacodylate buffer and secondarily fixed for 3 h 
in osmium tetroxide (1%) in sodium cacodylate 
buffer (pH 7.3, 0.1 M). Then samples were 
washed with acetate buffer (pH 5.0, 0.1 M) and 
further fixed in uranyl acetate (0.5%) in the 
same buffer for 1 h. Dehydration was carried out 
with increasing concentrations of ethanol. After 
passage through propylene oxide, the samples 
were embedded in Epon-Araldite with the use of 
SPI-Pon as an Epon 812 substitute.  Thin 
sections were made with glass or diamond 
knives and stained with aqueous uranyl acetate 
(2%) and Reynold’s lead citrate. The stained 
sections were assessment and photographed with 
a JEOL 100-SX electron microscope. 
DISCUSSION 
Cytotoxicity 
In order to evaluate the cytotoxicity of 
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compound and also to select a dose for 
irradiation, the glioma cells, a clinically 
relevant tumor cell line for BNCT. 
A low cytotoxicity for a boronated agent 
is an important parameter in BNCT so that 
boron concentrations within tumors can be 
maximised. The cytotoxic activity of the 
boron compounds was determined using the 
MTT assay which evaluates the reduction of 
the tetrazolium salt by a mitochondrial 
dehydrogenase in metabolic active cells to 
insoluble formazan crystals was described by E. 
Vega-Avila et al. The cellular viability in the 
presence of the tested compounds was compared 
to that observed in controls (no additions) and 
the cellular viability (%) was calculated. As an 
example of the corresponding inhibition curves 
(effect on cellular viability vs. compound 
concentration) compounds can be seen in Figure 
2. 
 
 
 
In vitro BNCT 
To assessment the potential of BNCT 
agents, their cytotoxic activities towards cells 
were tested after neutron irradiation for 5 h at 
room temperature. Compounds were added at 
an equimolar concentration of 200 μM. The 
cellular viability was determined by the MTT 
assay after 24 h incubation in compound free 
medium. The viability of cells after neutron 
irradiation in the presence or absence of the 
tested compounds was compared to that 
observed in controls (cells only). Neutron 
irradiation induced an increase in the cytotoxic 
effect. As an example the viability of cells can 
be seen in Figure. 3. 
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Cellular distribution by ICP-MS 
Comparative cellular distribution studies 
of compound with the cells were conducted in 
order to determine the boron content 
delivered by the compound.  As an example 
the boron content was determined by 
inductively-coupled plasma mass 
spectroscopy (ICP-MS) in cytosol, 
membrane/particulate, nucleus and 
cytoskeletal fractions isolated from cells after 
6 h exposure to the compounds at 200 μM can 
be seen as an example in Figure. 4 
This result indicates that compounds can 
target cellular components present mainly at the 
membrane or cytoskeleton, but without a 
cytotoxic effect, a factor that is critical in the 
design of new agents for BNCT. Moreover, the 
concentration of boron deposited into the cell is 
adequate for this therapeutic modality. We 
calculated an uptake of approx. 1.4 × 1011 B 
atoms and consequently 2.8 × 1010  10B atoms 
per cell, an amount superior to the recommended 
concentration of 108–109 10B atoms according 
to E. L. Crossley et al. 
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Cytotoxicity 
The cellular trafficking of compounds 
was assessment by timelapse confocal 
fluorescence microscopy in live cells by 
taking advantage of their fluorescence 
properties. As an example depicted in Figure. 5,  
rapidly accumulates in the glioblastoma cells but 
not significantly in the nucleus. 
 
 
CONCLUSIONS 
Glioblastoma has long been the focus of 
BNCT research due to its radioresistance and 
infiltrative growth pattern. Clinical and 
experimental BNCT using BSH and BPA has 
shown potential but no proven therapeutic 
advantages. Research is therefore justified to 
further evaluate this experimental treatment 
modality. Recent literature reports discussed 
some of the more recent results and progress 
in BNCT, providing hope for this unique and 
exciting mode of clinical therapy. Two 
criteria must be fulfilled for clinical 
application of BNCT: an adequate source of 
high flux thermal neutrons along with a boron 
carrier that is able to concentrate in glioma 
cells and tissues. A high concentration of 
boron within tumor cells should be obtained 
in order to maximize the therapeutic effect. 
The compound enter the cells and deposit 
an adequate amount of B atoms (2.8 × 1010 10B 
atoms per cell) superior to the recommended 
concentration of 108–109 10B atoms.  The 
compound  also fulfilled the requirement of a 
low cytotoxicity. Therefore, although further 
studies need to be done, this results as an 
example suggest that compound 
carboranylmethylbenzo[b]acridin-12(7H)-one 
may be considered as a lead compound for a 
new generation of BNCT agents although 
implications for therapy applications are at 
present obviously only exploratory. 
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